Compare Amgen, Inc. (AMGN) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Orion Office REIT Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Orion Office REIT Inc trades at $2.7 (market cap $156.28M). The key difference: Amgen, Inc. is far larger — about 1254.9× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (2.91%). Which is the better fit depends on your goals.
| AMGN | ONL | |
|---|---|---|
Market Cap | $196.12B | $156.28M |
Sector | Health | Real Estate |
52-Week High | $388.16 | $3.04 |
52-Week Low | $271.18 | $1.93 |
Enterprise Value | $241.41B | $639.94M |
Dividend Yield | 2.77% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ONL trades at $2.75, down 1.08% on the day, with a neutral technical signal and bearish moving averages. The company reported a net loss of $139.31 million in 2025, with revenue declining to $147.65 million. Despite negative profitability, the stock trades at a low price-to-book ratio of 0.26 and recently announced a $0.02 dividend. Strategic reviews and portfolio repositioning are ongoing, as noted in recent earnings calls (Business Wire, 2026-05-07).
Outlook remains challenged by persistent losses and high debt, but strategic asset sales and refinancing improvements offer potential stabilization. Risks include further revenue declines and office sector headwinds, while analyst sentiment is evenly split between buy and hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
